ElevenLabs vs Synthesia: Revenue, Efficiency & Valuation

Compare ElevenLabs and Synthesia on ARR per employee, revenue, headcount, valuation, funding, category rank, and source evidence.

Metric differences

ElevenLabs produces $679K ARR per employee versus $227K for Synthesia, a directional gap of $452K per employee.

CompanyARR/employeeARREmployeesValuationFunding
ElevenLabs$679K$500M736$11B$500M Series D + extension (Feb–May 2026)
Synthesia$227K$150M661$4B$200M Series E (Jan 2026)

Company summaries

ElevenLabs

ElevenLabs is an AI voice synthesis and audio generation platform that creates ultra-realistic speech, sound effects, and voice clones for media, gaming, publishing, and enterprise applications. The platform serves content creators, media companies, game studios, and enterprises that need high-quality synthetic voice generation in dozens of languages and voice styles. ElevenLabs' technology produces speech that is virtually indistinguishable from human recordings, enabling applications from audiobook narration to real-time voice dubbing and conversational AI agents. The company has grown rapidly to become the market leader in AI voice generation, with its API powering voice capabilities in thousands of applications and a growing focus on safety measures to prevent misuse.

Synthesia

Synthesia is an AI video generation platform that creates professional-quality videos from text scripts using photorealistic AI avatars and voiceovers in over 120 languages. The platform is used by enterprise L&D teams, marketing departments, and internal communications groups that need to produce video content at scale without the cost and logistics of traditional video production. Synthesia eliminates the need for cameras, studios, and actors by generating on-screen presenters entirely through AI, enabling companies to update training videos in minutes rather than weeks. The company has become a category leader in enterprise AI video with over 50,000 business customers and a focus on trust, safety, and content authenticity.

Evidence and next steps